BIRMINGHAM, Ala., Sept. 22 /PRNewswire/ — Atherotech
Diagnostics Lab will exhibit its VAP® Cholesterol Test in booth
121 at the Florida Osteopathic Medical Association (FOMA) Mid-Year
Seminar held September 24-26 at the Grand Hyatt Tampa Bay in Tampa,
Fla.
FOMA is the state association for osteopathic physicians in
Florida and has been serving osteopathic physicians since 1904. The
2010 seminar will address advances in the science and art of
osteopathic medicine. Cholesterol expert Paul Ziajka, M.D., who
utilizes the VAP Test at the Florida Lipid Institute, will address
“Inflammatory Markers and the Risk of Atherosclerosis” during the
conference.
Atherotech’s VAP Cholesterol Test is the only expanded lipid
test that routinely reports directly measured LDL-C, which is
included in the 22 separate components of cholesterol — all
reported at no additional cost. Cholesterol subclasses include
Lp(a), apoB, apoA1, and the apoB/apoA1 ratio, making the VAP Test
the only lipid profile that routinely reports all three lipid
parameters — LDL, non-HDL and apoB — considered
necessary by the American Diabetes Association and American College
of Cardiology. The comprehensive lipid profile also identifies
markers of metabolic syndrome, often associated with early
diabetes.
“The VAP Test goes far beyond the standard cholesterol test,
providing a valuable research tool for cardiovascular science and
detailed information for refining the clinical assessment of
cardiovascular risk,” said Atherotech Medical Advisory Board Member
Gary H. Gibbons, M.D., a nationally recognized clinician-scientist
and Director of the Cardiovascular Research Institute in Atlanta.
“Because of its ability to report on dozens of cholesterol
subclasses, the VAP Test holds great promise for playing a key role
in advancing the understanding of heart disease risk and addressing
disparities in cardiovascular health.”
Atherotech provides physicians with a
‘/>”/>